Emergent BioSolutions Inc.
NYSE:EBSBiotechnology
-$0.21 today
- Market cap
- $282.78M
- Beta
- 2.33
- P/E (TTM)
- -47.9
- EPS (TTM)
- -$0.17
Volume 0.82M
Average 0.78M
EBS Net Income
Bottom-line profit after all expenses, interest, and taxes.
Emergent BioSolutions Inc.NYSE: EBS
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income dips below year-ago levels
Q1 FY2026 net income of $6.8M fell 90.0% year over year, behind the +93.5% change in trailing-twelve-month net income.
Context
- Net income amounted to 7.1% of revenue in FY2025, down 11.2 pp from a year earlier.
- Net income increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 2 analysts of $15.59M (-70.4%) for the fiscal year ending Dec 2026, a slowdown from the +127.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $6.8M+112.5% QoQ
- Last fiscal yearDec 2025
- $52.6M+127.6% YoY
- LTMMar 2026
- -$8.6M+93.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -90.0% | +63.7% | +153.7 pp |
| 1 year | +127.6% | -70.4% | -198.0 pp |
| 3-year CAGR | — | +19.1% | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- 52.6M USD
- Year-over-year change
- +127.6%
- 4-year CAGR
- -30.0%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 52.6M | +127.6% |
| FY2024 | 2024-12-31 | (190.6M) | +74.9% |
| FY2023 | 2023-12-31 | (760.5M) | -259.4% |
| FY2022 | 2022-12-31 | (211.6M) | -196.4% |
| FY2021 | 2021-12-31 | 219.5M | — |
Net Income vs competitors
How EBS compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +93.5% is the 4th highest of 11, against a peer median of -16.9%.
- Net income amounts to 1.3% of revenue for EBS, versus a peer median of 21.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $364.23M USD | +879.7% | — | 121.5% | |
| LTM Mar 2026 | $20.26M USD | -58.2% | -11.8% | 21.6% | |
| LTM Mar 2026 | -$284K USD | +98.2% | +33.6% | 0.1% | |
| LTM Mar 2026 | -$7.42M USD | +95.2% | — | 1.8% | |
| LTM Mar 2026 | -$8.6M USD | +93.5% | — | 1.3% | |
| LTM Mar 2026 | -CA$10.98M CAD | +89.7% | — | 1.2% | |
| LTM Mar 2026 | -$44.17M USD | -6.7% | — | — | |
| LTM Mar 2026 | -$68.91M USD | -27.1% | — | 137.1% | |
| LTM Mar 2026 | -$151.18M USD | -37.1% | — | 260.9% | |
| LTM Mar 2026 | -$178.95M USD | -29.9% | — | — | |
| LTM Mar 2026 | -$185.15M USD | -43.6% | — | — | |
| Peer median (excluding EBS) | — | -16.9% | +10.9% | 21.6% | |
Competitors are the stored peer set for EBS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.77B | 1.12B | 1.05B | 1.04B | 742.9M |
| Cost of Revenue | 980.4M | 644.5M | 689.3M | 668.2M | 392.3M |
| Gross Profit | 793.2M | 473M | 360M | 375.4M | 350.6M |
| Gross Margin | 44.7% | 42.3% | 34.3% | 36.0% | 47.2% |
| Research & Development | 235.2M | 188.3M | 111.4M | 70.7M | 53.8M |
| Selling, General & Admin | 348.7M | 339.5M | 356.7M | 298.7M | 186.6M |
| Operating Expenses | 451.8M | 643M | 1.09B | 484.1M | 240.4M |
| Depreciation & Amortization | 118.2M | 125M | 121.1M | 105.6M | 98.3M |
| EBITDA | 504.2M | 15.7M | (47M) | 53.4M | 240.4M |
| EBITDA Margin | 28.4% | 1.4% | -4.5% | 5.1% | 32.4% |
| Operating Income | 341.4M | (170M) | (726.4M) | (108.7M) | 110.2M |
| Operating Margin | 19.2% | -15.2% | -69.2% | -10.4% | 14.8% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 34.5M | 37.3M | 87.9M | 71M | 59.3M |
| Other Income / Expenses | (38.2M) | (49M) | (4.8M) | (34.2M) | (27.4M) |
| Income Before Tax | 303.2M | (219M) | (731.2M) | (142.9M) | 82.8M |
| Pre-Tax Margin | 17.1% | -19.6% | -69.7% | -13.7% | 11.1% |
| Income Tax Expense | 83.7M | (7.4M) | 29.3M | 47.7M | 30.2M |
| Net Income | 219.5M | (211.6M) | (760.5M) | (190.6M) | 52.6M |
| Net Margin | 12.4% | -18.9% | -72.5% | -18.3% | 7.1% |
| EPS (Basic) | 4.10 | (4.22) | (14.85) | (3.60) | 0.98 |
| EPS (Diluted) | 4.06 | (4.22) | (14.85) | (3.60) | 0.93 |
| Weighted Avg Shares | 53.5M | 50.1M | 51.2M | 53M | 53.5M |
| Weighted Avg Shares (Diluted) | 54.1M | 50.1M | 51.2M | 53M | 56.7M |
Emergent BioSolutions Inc.
NYSE:EBS
Intrinsic Alpha fair value
Locked
Current Price
$5.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.